Abstract:Myostatin (MSTN) is a transforming growth factor (TGF)-β superfamily member that acts as a negative regulator of muscle growth and may play a role in cardiac remodeling. We hypothesized that inhibition of activin type II receptors (ACTRII) to reduce MSTN signaling would reduce pathological cardiac remodeling in experimental heart failure (HF). C57BL/6J mice underwent left anterior descending coronary artery ligation under anesthesia to induce myocardial infarction (MI) or no ligation (sham). MI and sham animals were each randomly divided into groups (n ≥ 10 mice/group) receiving an ACTRII or ACTRII/TGFβ receptor-signaling inhibiting strategy: 1) myo-Fc group (weekly 10 mg/kg Myo-Fc) or 2) Fol + TGFi group (daily 12 µg/kg follistatin plus 2 mg/kg TGFβ receptor inhibitor), versus controls. ACTRII/TGFBR signaling inhibition preserved cardiac function by echocardiography and prevented an increase in brain natriuretic peptide (BNP). ACTRII/TGFBR inhibition resulted in increased phosphorylation (P) of Akt and decreased P-p38 mitogen-activated protein kinase (MAPK) in MI mice. In vitro, Akt contributed to P-SMAD2,3, P-p38, and BNP regulation in cardiomyocytes. ACTRII/TGFBR inhibition increased sarco/endoplasmic reticulum Ca2+-ATPase (SERCA2a) levels and decreased unfolded protein response (UPR) markers in MI mice. ACTRII/TGFBR inhibition was associated with a decrease in cardiac fibrosis and fibrosis markers, connective tissue growth factor (CTGF), type I collagen, fibronectin, α-smooth muscle actin, and matrix metalloproteinase (MMP)-12 in MI mice. MSTN exerted a direct regulation on the UPR marker eukaryotic translation initiation factor-2α (eIf2α) in cardiomyocytes. Our study suggests that ACTRII ligand inhibition has beneficial effects on cardiac signaling and fibrosis after ischemic HF.NEW & NOTEWORTHY Activin type II receptor ligand inhibition resulted in preserved cardiac function, a decrease in cardiac fibrosis, improved SERCA2a levels, and a prevention of the unfolded protein response in mice with myocardial infarction.

Two Activin Type 2B Receptors from Sea Bream Function Similarly in vitro

Molecular Cloning of Activin Type I and Type II Receptors and Differential Regulation of Their Expression by Activin in Grass Carp Pituitary Cells.

Functional redundancy of type I and type II receptors in the regulation of skeletal muscle growth by myostatin and activin A

Expression of Type I and Type IB Receptors for Activin in Midgestation Mouse Embryos Suggests Distinct Functions in Organogenesis

Molecular Cloning, Characterization and Tissue Distribution of Six Splice Variants of Activin Type Iia Receptor (actriia) from Grass Carp (ctenopharyngodon Idellus)

Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B

Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy

Activin E is a transforming growth factor β ligand that signals specifically through activin receptor-like kinase 7

Functional Antagonism Between Activin And Osteogenic Protein-1 In Human Embryonal Carcinoma Cells

Activin receptor type 2A (ACVR2A) functions directly in osteoblasts as a negative regulator of bone mass

Molecular characteristic of activin receptor IIB and its functions in growth and nutrient regulation in Eriocheir sinensis

Activin A more prominently regulates muscle mass in primates than does GDF8

Activin A induces a non-fibrotic phenotype in smooth muscle cells in contrast to TGF-β

Activin E is a TGFβ ligand that signals specifically through activin receptor-like kinase 7

Characterization and Function of the Interaction of Angiogenin with Alpha-Actinin 2

Activin Signaling Pathway Specialization During Embryonic and Skeletal Muscle Development in Rainbow Trout (Oncorhynchus mykiss)

Activin type II receptor ligand signaling inhibition after experimental ischemic heart failure attenuates cardiac remodeling and prevents fibrosis

Follistatins neutralize activin bioactivity by inhibition of activin binding to its type II receptors

Characterization of Type I Receptors for Transforming Growth Factor-β and Activin

Differential Regulation of Mouse Pancreatic Islet Insulin Secretion and Smad Proteins by Activin Ligands.

Activin A regulation of gonadotropin-releasing hormone synthesis and release in vitro